Agenus, Inc. (Nasdaq: AGEN)
Agenus, Inc. (Nasdaq: AGEN) is an immuno-oncology company dedicated to discovering and developing therapies that harness the body’s immune system to fight cancer. The company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies, and vaccines targeting a broad range of cancer types. With a focus on novel combination therapies, Agenus aims to enhance the effectiveness of existing treatments and address unmet medical needs. Its approach leverages scientific innovation, partnerships, and a robust pipeline to drive advances in cancer immunotherapy.
At Agenus, we’re redefining what’s possible in cancer treatment, helping patients with advanced, treatment-resistant tumors achieve deep, lasting responses.
We Turn "Cold" Tumors...HOT!
One Patient’s Story:
A 40-year-old patient diagnosed with Stage III MSS colon cancer, with an 8 cm tumor, received one dose of Botensilimab (BOT) and three doses of Balstilimab (BAL) over seven weeks prior to surgery. This was with no prior or concurrent treatment. The tumor showed significant immune activation and regression, exemplifying the power of BOT/BAL to transform outcomes—even in cancers once considered unresponsive to immunotherapy.
Why BOT/BAL Matters for Patients
Activating the Immune System in Cold Tumors
BOT/BAL is designed to awaken the immune system in “cold” tumors—those previously unresponsive to immunotherapy—bringing the benefits of immune-based treatment to more people with solid tumors.
Real-World Results
-
Over 1,100 patients treated with BOT and BAL
-
Demonstrated clinical benefit in 9 solid tumor types
-
In late-line MSS colorectal cancer, BOT/BAL showed a median overall survival of 21.2 months, compared to 14 months with current standard care
Designed for Safety and Convenience
BOT/BAL’s favorable safety profile allows for treatment even before surgery (neoadjuvant setting), offering new options without the burden of high toxicity.
Backed by the FDA
The BOT/BAL program has received Fast Track designation for third-line MSS colorectal cancer. Discussions are ongoing to align on both accelerated and full approval pathways.
Botensilimab Mechanism of Action
